Stocktoria
GT Biopharma, Inc. GTBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-10-22
GT Biopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $3.5M | $5.8M | $6.5M | $8.8M | $9.6M |
| SG&A expense | $8.9M | $8.6M | $7.1M | $12.4M | $47.9M |
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | -$57.5M |
| Interest expense | — | — | $213,000 | $8,000 | $718,000 |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M | -$58.0M |
| EPS (diluted) | $-6.68 | $-6.94 | $-5.64 | $-19.66 | — |
| Operating cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | -$15.6M |
| Cash & equivalents | $6.8M | $4.0M | $1.1M | $5.7M | $9.0M |
| Total assets | $8.1M | $4.2M | $14.1M | $16.7M | $32.2M |
| Total liabilities | — | — | $6.6M | $5.0M | $10.3M |
| Shareholders' equity | $5.8M | -$1.7M | $7.5M | $11.7M | $21.9M |
Source: SEC EDGAR filings · CIK 0000109657 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.